This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Domperidone for Gastroparesis in Solid Organ Transplantation

This study has been terminated.
(Lack of perceived need for domperidone in this population)
Information provided by (Responsible Party):
David J. Lederer, M.D., Columbia University Identifier:
First received: October 31, 2007
Last updated: June 17, 2015
Last verified: June 2015
The purpose of this study is to examine the clinical response to domperidone in solid organ transplant recipients with gastroparesis.

Condition Intervention
Gastroparesis Gastroesophageal Reflux Drug: domperidone

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Domperidone for Gastroparesis Associated With Solid Organ Transplantation

Resource links provided by NLM:

Further study details as provided by David J. Lederer, M.D., Columbia University:

Primary Outcome Measures:
  • Symptomatic Improvement [ Time Frame: 2 months ]
    The primary endpoint of the study is the achievement of a symptom grade of less then or equal to 3.

Enrollment: 6
Study Start Date: March 2007
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Domperidone Arm
Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with significant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with significant renal impairment will be 20mg twice a day.
Drug: domperidone
10mg orally four times per day

Detailed Description:

After heart or lung transplantation, the stomach tends to empty much slower than normal. This slow emptying is called "gastroparesis." Gastroparesis is uncomfortable and often leads to nausea and vomiting. In addition to drastically impacting quality of life, severe nausea and vomiting can also lead to malnutrition and an inability to take oral medications, contributing to complications of transplantation. Treatments for gastroparesis include both medical and surgical therapies that work for some but not all patients.

Domperidone is a peripheral D2 antagonist that improves the emptying of the stomach in patients with gastroparesis. Domperidone is not FDA approved at this time. Some patients have developed lifethreatening abnormal heart rhythms after receiving domperidone intravenously. This problem has not been seen with domperidone given by mouth.

We propose to administer domperidone by mouth at standard doses to solid organ transplant patients who have gastroparesis that is not responsive to standard medical therapies or who experience adverse drug side effects. This study will not be blinded (open-label) and has a single treatment arm (no control or placebo group).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • gastroparesis or gastroesophageal reflux that is refractory to standard therapy.
  • signed informed consent

Exclusion Criteria:

  • serious cardiac arrhythmias
  • clinically significant bradycardia, sinus node dysfunction, or heart block.
  • prolonged QTc
  • clinically significant electrolyte disorders.
  • gastrointestinal hemorrhage or obstruction.
  • prolactinoma
  • pregnant or breast feeding female
  • known allergy to domperidone.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00552422

United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
David J. Lederer, M.D.
Principal Investigator: David J Lederer, M.D. Columbia University
  More Information

Responsible Party: David J. Lederer, M.D., Herbert Irving Assistant Professor of Medicine and Epidemiology, Columbia University Identifier: NCT00552422     History of Changes
Other Study ID Numbers: AAAC3728
Study First Received: October 31, 2007
Results First Received: June 2, 2015
Last Updated: June 17, 2015

Keywords provided by David J. Lederer, M.D., Columbia University:
gastroesophageal reflux

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Neurologic Manifestations
Signs and Symptoms
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 20, 2017